22 results
8-K
EX-99.1
TSBX
Turnstone Biologics Corp
13 May 24
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
5:03pm
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include
10-K
2023 FY
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
clinical trials;
initiation of investigations by U.S. and foreign regulators;
costs to defend the related litigation;
diversion of management’s time … in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators may seek to amend or modify the terms of any
10-K
2023 FY
EX-4.3
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit
8-K
EX-99.1
3ghn3b2l7rt 8j
21 Mar 24
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
5:14pm
10-Q
g34o4sepj
1 Sep 23
Quarterly report
4:39pm
424B4
up2qf82l8
21 Jul 23
Prospectus supplement with pricing info
7:14pm
S-1/A
2maq2y
23 Jun 23
IPO registration (amended)
9:49pm
S-1
EX-2.1
i1owcn4klriy
12 Jun 23
IPO registration
4:28pm
S-1
EX-10.9
mxl1jvfmwbq9
12 Jun 23
IPO registration
4:28pm
S-1
EX-10.8
kjwdjfys
12 Jun 23
IPO registration
4:28pm
S-1
EX-10.2
isjtn
12 Jun 23
IPO registration
4:28pm
S-1
2cfijq4wh1b 9euo22cg
12 Jun 23
IPO registration
4:28pm
DRS
xbafk1w1 o7xe
15 May 23
Draft registration statement
12:00am
DRS
EX-10.2
mpipfw8180cdv
15 May 23
Draft registration statement
12:00am
DRS
EX-10.9
67y c3qazkkdnwx6vda
15 May 23
Draft registration statement
12:00am